Practice

Regence: Biosimilar Adoption Reduces $37 Million in Annual Spending

November 28th 2022

By Skylar Jeremias

Regence found that implementing strategies to increase its biosimilar adoption rate reduced spending on specialty drugs by $37 million annually. The organization is the latest example of how biosimilar use has contributed to significant savings.

Dr Ryan Haumschild Explains How Technology Can Help Practices Juggle Multiple Biosimilars

November 20th 2022

By Skylar Jeremias

Video

Technology utilizing electronic medical records pathways can be useful for practices struggling to manage multiple biosimilars for the same reference product, according to Ryan Haumschild, PharmD, MS, MBA, from Emory Healthcare and Winship Cancer Institute.

Administration for Pegfilgrastim Biosimilars Should Minimize Clinic Visits, Consider Patients’ Preferences

November 19th 2022

By Deana Ferreri, PhD

Article

A review explored the 3 main administration options for pegfilgrastim biosimilars, finding that providers should consider the ease and frequency to which patients will need to travel to a clinic for administration as well as their preferences when choosing a mode of administration.

AMCP Nexus Abstracts Investigate Adoption, Budget Impact of Biosimilars

November 8th 2022

By Skylar Jeremias

Article

Abstracts presented at the Academy of Managed Care Pharmacy (AMCP) Nexus meeting explored the adoption of infliximab biosimilars, utilization patterns of bevacizumab biosimilars in ophthalmology and oncology settings, and the budget impact of transferring patients to a natalizumab biosimilar from the originator.

AAM Report: Biosimilars, Generics Generated Billions of Dollars in Savings in 2021

November 1st 2022

By Skylar Jeremias

Article

Biosimilar and generic drugs accumulated $373 billion in savings in 2021, $7 billion of which can be attributed to biosimilars alone, according to a report from the Association for Accessible Medicines (AAM).

Dr Ryan Haumschild: What Health Systems Can Learn From Emory Healthcare's Biosimilar Strategy

October 30th 2022

By Skylar Jeremias

Video

Ryan Haumschild, PharmD, MS, MBA, from Emory Healthcare and Winship Cancer Institute, offers advice to health systems on how they can incorporate some of Emory Healthcare's strategies to promote biosimilar uptake.

Cardinal Health Reports Increased Confidence in Biosimilars Among Rheumatologists

October 22nd 2022

By Skylar Jeremias

Article

A report from Cardinal Health tells that rheumatologists are more familiar and confident in biosimilars compared with 2020, showing that education efforts are effective and that rheumatologists are more willing to prescribe biosimilars to their patients.

Order of Operations: Managing Biosimilars While Maintaining Operational Efficiency

October 16th 2022

By Skylar Jeremias

Podcast

In this podcast episode, Kathy Oubre, MS, CEO of Pontchartrain Cancer Center, discussed the stresses that practices and clinics face when trying to manage biosimilars as well as some policy considerations that administrators should keep in mind as more biosimilars enter the market and are added to formularies.

Dr Ryan Haumschild Compares Viewpoints on Biosimilar Value Between Stakeholders

October 4th 2022

By Skylar Jeremias

Video

Ryan Haumschild, PharmD, MS, MBA, from Emory Healthcare and Winship Cancer Institute, explains how stakeholders may view the economic value of biosimilars differently based on their goals and his predictions for how biosimilar utilization will develop in the future.

Policy Harmonization, Clarification Could Aid Biosimilar Uptake Efforts

September 23rd 2022

By Skylar Jeremias

Article

Realigning definitions and policies across regulatory agencies and developing a better understanding of how different stakeholders approach biosimilars could help get more patients and providers on board with using biosimilars, according to panelists at the DIA Biosimilars Conference.